Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD of Barinthus Biotherapeutics plc. from Q1 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
Barinthus Biotherapeutics plc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and change rate from Q1 2020 to Q3 2025.
  • Barinthus Biotherapeutics plc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 30 Sep 2025 was -$17.5M, a 1740% decline year-over-year.
  • Barinthus Biotherapeutics plc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending 30 Sep 2025 was -$76.2M, a 80.2% decline year-over-year.
  • Barinthus Biotherapeutics plc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2024 was -$63.6M, a 0.67% decline from 2023.
  • Barinthus Biotherapeutics plc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$63.2M, a 222% decline from 2022.
  • Barinthus Biotherapeutics plc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$19.6M, a 66.2% increase from 2021.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)

Barinthus Biotherapeutics plc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$76.2M -$17.5M -$18.6M -1740% 01 Jul 2025 30 Sep 2025 10-Q 07 Nov 2025
Q2 2025 -$57.6M -$12.8M +$3.93M +23.4% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 -$61.6M -$15M +$2.06M +12.1% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025
Q4 2024 -$63.6M -$30.9M -$21.3M -225% 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025
Q3 2024 -$42.3M $1.07M +$22.9M 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2025
Q2 2024 -$65.2M -$16.8M +$1.44M +7.89% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025
Q1 2024 -$66.7M -$17.1M -$3.46M -25.5% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025
Q4 2023 -$63.2M -$9.51M -$6M -171% 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025
Q3 2023 -$57.2M -$21.9M -$10.2M -87.5% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024
Q2 2023 -$47M -$18.2M -$17.1M -1579% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024
Q1 2023 -$29.9M -$13.6M -$10.2M -303% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024
Q4 2022 -$19.6M -$3.51M +$11.1M +75.9% 01 Oct 2022 31 Dec 2022 10-K 20 Mar 2024
Q3 2022 -$30.7M -$11.7M -$650K -5.9% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 -$30M -$1.08M +$14.8M +93.2% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023
Q1 2022 -$44.8M -$3.37M +$13.3M +79.8% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023
Q4 2021 -$58.1M -$14.6M -$4.08M -38.9% 01 Oct 2021 31 Dec 2021 10-K 24 Mar 2023
Q3 2021 -$54M -$11M -$11.2M -5131% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 -$42.8M -$15.8M -$12.1M -325% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022
Q1 2021 -$30.7M -$16.7M -$12.2M -272% 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022
Q4 2020 -$18.5M -$10.5M 01 Oct 2020 31 Dec 2020 10-K 25 Mar 2022
Q3 2020 $219K 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 -$3.73M 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021
Q1 2020 -$4.49M 01 Jan 2020 31 Mar 2020 10-Q 14 Jun 2021

Barinthus Biotherapeutics plc. Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$63.6M -$425K -0.67% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025
2023 -$63.2M -$43.6M -222% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025
2022 -$19.6M +$38.5M +66.2% 01 Jan 2022 31 Dec 2022 10-K 20 Mar 2024
2021 -$58.1M -$39.6M -214% 01 Jan 2021 31 Dec 2021 10-K 24 Mar 2023
2020 -$18.5M 01 Jan 2020 31 Dec 2020 10-K 25 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.